SCHEMBL4010466

SCHEMBL4010466

COC(=O)C(O)(CC(C)OC1CCCCO1)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.43
ALDH1A1 P00352 1/20 0.38
KCNN4 O15554 1/20 0.38
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 3/20 0.36
GAA P10253 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CHRM2 P08172 3/20 0.36
CHRM1 P11229 2/20 0.36
CHRM3 P20309 2/20 0.36
CHRM4 P08173 1/20 0.36
KCNH2 Q12809 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
SCN1A P35498 1/20 0.36
SCN2A Q99250 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7050550 0.73 SIGMAR1 (0.39) SLC6A3HPGDMEN1KMT2ACYP1A2
SCHEMBL5686699 0.73 SLC6A3 (0.45) SLC6A3KCNN4KEAP1NFE2L2MEN1
SCHEMBL4009225 0.73 KCNN4 (0.55) ALDH1A1KCNN4GAAMEN1KMT2A
SCHEMBL8762920 0.73 ALDH1A1 (0.41) SLC6A3ALDH1A1MEN1KMT2ACHRM2
SCHEMBL14233517 0.71 SLC6A3 (0.61) SLC6A3ALDH1A1HPGDGAAKMT2A
SCHEMBL1743566 0.71 SLC6A3 (0.61) SLC6A3ALDH1A1HPGDGAAKMT2A
SCHEMBL14211627 0.71 SLC6A3 (0.61) SLC6A3ALDH1A1HPGDGAAKMT2A
SCHEMBL4013121 0.71 KCNN4 (0.49) SLC6A3ALDH1A1KCNN4KEAP1NFE2L2
SCHEMBL29198498 0.71 EPHX2 (0.36) SLC6A3ALDH1A1HPGDMEN1KMT2A
SCHEMBL29925426 0.71 EPHX2 (0.36) SLC6A3ALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781617-A4 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA NV (BE) 2009-06-24 EP disclosed
EP-1781617-A2 ALPHA, BETA-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-09 EP disclosed
WO-2006004742-A2 α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION JANSSEN PHARAMCEUTICA N.V. (BE) 2006-01-12 WO disclosed
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration JANSSEN PHARMACEUTICA N.V. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004195-A1 Alpha,beta-unsaturated esters and acids by stereoselective dehydration CCKAR, CCKBR, FFAR1 SLC6A3 2319/4885ALDH1A1 597/4885KCNN4 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.